{"id":"ii-consolidation-hidarac","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Neurotoxicity (cerebellar syndrome, encephalopathy)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HiDAraC delivers high-dose cytarabine, a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation. This consolidation phase follows induction therapy to eliminate residual leukemic cells and improve disease-free survival in AML patients who have achieved remission.","oneSentence":"II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:36.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) consolidation therapy in first remission"}]},"trialDetails":[{"nctId":"NCT02072811","phase":"PHASE3","title":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"dr hab. n. med. Agnieszka Wierzbowska","startDate":"2014-02","conditions":"Acute Myeloid Leukemia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- Cytosine arabinoside [Ara-C]","- Cladribine"],"phase":"phase_3","status":"active","brandName":"II Consolidation HiDAraC","genericName":"II Consolidation HiDAraC","companyName":"dr hab. n. med. Agnieszka Wierzbowska","companyId":"dr-hab-n-med-agnieszka-wierzbowska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia. Used for Acute myeloid leukemia (AML) consolidation therapy in first remission.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}